0000950170-22-013411 Sample Contracts

Royalty Purchase Agreement By and Between Rare Delaware Inc. Ultragenyx Pharmaceutical Inc. and OCM LS23 Holdings LP Dated as of July 14, 2022

Royalty Purchase Agreement • July 29th, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York

• Contract Type
  Royalty Purchase Agreement
• Filed
  July 29th, 2022
• Company
  Ultragenyx Pharmaceutical Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Royalty Purchase Agreement (this “Agreement”), dated as of July 14, 2022 (the “Effective Date”), is made and entered into by and among Rare Delaware Inc., a Delaware corporation (“Seller”), Ultragenyx Pharmaceutical Inc., a Delaware corporation and the direct parent of Seller (“Ultragenyx”) and OCM LS23 Holdings LP, an Ontario limited partnership (“Buyer”).

UNIT PURCHASE AGREEMENT by and among ULTRAGENYX PHARMACEUTICAL INC., GENETX BIOTHERAPEUTICS LLC, THE UNITHOLDERS LISTED ON SCHEDULE A and

Unit Purchase Agreement • July 29th, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Texas

• Contract Type
  Unit Purchase Agreement
• Filed
  July 29th, 2022
• Company
  Ultragenyx Pharmaceutical Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Texas

THIS UNIT PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of this 15th day of July, 2022, by and among Ultragenyx Pharmaceutical Inc., a Delaware corporation (“Buyer”), GeneTx Biotherapeutics LLC, a Delaware limited liability company (the “Company”), the holders of Units listed on Schedule A (the “Unitholders”), and Deborah A. Guagliardo, an individual, solely in her capacity as representative of the Unitholders (the “Representative”).